Centessa Pharmaceuticals PLC (CNTA) has a current Price-to-Book (P/B) ratio of 10.56. Compared to its 3-year average P/B ratio of 4.64, the current P/B ratio is approximately 127.71% higher. Relative to its 5-year average P/B ratio of 4.16, the current P/B ratio is about 154.07% higher. Centessa Pharmaceuticals PLC (CNTA) has a Forward Free Cash Flow (FCF) yield of approximately -5.24%. Compared to its 3-year average FCF yield of -16.91%, the current FCF yield is approximately -69.04% lower. Relative to its 5-year average FCF yield of -21.70%, the current FCF yield is about -75.88% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CNTA competitors is 768.92, providing a benchmark for relative valuation. Centessa Pharmaceuticals PLC Corp (CNTA.O) exhibits a P/S ratio of 4511.78, which is 486.77% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CNTA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CNTA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CNTA currently overvalued or undervalued?

What is Centessa Pharmaceuticals PLC (CNTA) fair value?

CNTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Centessa Pharmaceuticals PLC (CNTA) is between to according to relative valuation method.

How does CNTA's valuation metrics compare to the industry average?

The average P/S ratio for CNTA's competitors is 768.92, providing a benchmark for relative valuation. Centessa Pharmaceuticals PLC Corp (CNTA) exhibits a P/S ratio of 4511.78, which is 486.77% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Centessa Pharmaceuticals PLC (CNTA) as of Mar 03 2026?

As of Mar 03 2026, Centessa Pharmaceuticals PLC (CNTA) has a P/B ratio of 10.56. This indicates that the market values CNTA at 10.56 times its book value.

What is the current FCF Yield for Centessa Pharmaceuticals PLC (CNTA) as of Mar 03 2026?

As of Mar 03 2026, Centessa Pharmaceuticals PLC (CNTA) has a FCF Yield of -5.24%. This means that for every dollar of Centessa Pharmaceuticals PLC's market capitalization, the company generates -5.24 cents in free cash flow.

What is the current Forward P/E ratio for Centessa Pharmaceuticals PLC (CNTA) as of Mar 03 2026?

As of Mar 03 2026, Centessa Pharmaceuticals PLC (CNTA) has a Forward P/E ratio of -14.61. This means the market is willing to pay $-14.61 for every dollar of Centessa Pharmaceuticals PLC's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Centessa Pharmaceuticals PLC (CNTA) as of Mar 03 2026?

As of Mar 03 2026, Centessa Pharmaceuticals PLC (CNTA) has a Forward P/S ratio of 4511.78. This means the market is valuing CNTA at $4511.78 for every dollar of expected revenue over the next 12 months.

CNTA Valuation